This company has been acquired
Tyme Technologies Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Wichtige Informationen
-6.9%
Wachstumsrate der Gewinne
5.4%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 17.0% |
Wachstumsrate der Einnahmen | n/a |
Eigenkapitalrendite | -32.6% |
Netto-Marge | n/a |
Letzte Ertragsaktualisierung | 30 Jun 2022 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger
Sep 15We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Aug 05TYME stock surges on merger agreement and Syros Pharmaceuticals
Jul 05Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives
May 26We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth
Mar 19Tyme Technologies Offers Incredible Risk-Reward
Dec 07Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Nov 19Tyme Technologies: The Market Missed The Bullish Memo
Aug 27We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate
Jul 19Tyme Technologies reports FY results
Jun 10Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount
May 29Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Mar 26Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?
Feb 19Tyme falls after equity offer as quarterly data indicate liquidity pressure
Feb 04Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections
Feb 03Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?
Feb 02Revisiting Tyme Technologies
Dec 17Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?
Dec 16Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?
Dec 09Tyme Technologies names new finance chief
Nov 30Aufschlüsselung der Einnahmen und Ausgaben
Wie Tyme Technologies Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 22 | 0 | -24 | 12 | 11 |
31 Mar 22 | 0 | -24 | 10 | 13 |
31 Dec 21 | 0 | -24 | 10 | 15 |
30 Sep 21 | 0 | -25 | 9 | 15 |
30 Jun 21 | 0 | -26 | 10 | 16 |
31 Mar 21 | 0 | -29 | 10 | 17 |
31 Dec 20 | 0 | -28 | 11 | 17 |
30 Sep 20 | 0 | -28 | 12 | 16 |
30 Jun 20 | 0 | -28 | 12 | 15 |
31 Mar 20 | 0 | -22 | 13 | 13 |
31 Dec 19 | 0 | -27 | 13 | 13 |
30 Sep 19 | 0 | -29 | 14 | 14 |
30 Jun 19 | 0 | -29 | 14 | 14 |
31 Mar 19 | 0 | -33 | 15 | 15 |
31 Dec 18 | 0 | -27 | 14 | 13 |
30 Sep 18 | 0 | -25 | 13 | 11 |
30 Jun 18 | 0 | -23 | 12 | 11 |
31 Mar 18 | 0 | -19 | 11 | 9 |
31 Dec 17 | 0 | -17 | 9 | 8 |
30 Sep 17 | 0 | -14 | 7 | 7 |
30 Jun 17 | 0 | -12 | 7 | 6 |
31 Mar 17 | 0 | -15 | 9 | 6 |
31 Dec 16 | 0 | -17 | 8 | 4 |
30 Jun 16 | 0 | -13 | 9 | 5 |
31 Mar 16 | 0 | -11 | 8 | 3 |
31 Dec 15 | 0 | -12 | 4 | 4 |
Qualität der Erträge: TYME is currently unprofitable.
Wachsende Gewinnspanne: TYME is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: TYME is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.
Beschleunigtes Wachstum: Unable to compare TYME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: TYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: TYME has a negative Return on Equity (-32.63%), as it is currently unprofitable.